Replies to post #235904 on Biotech Values

[dewophile]

I think there is skepticism about enrollment in the RSV trial
Also recent ABUS data doesn’t help
Now covid seems to have less of a need for an antiviral in a few years
I still think enough irons in the fire to get a hit. And most of the opportunities they are going after are huge so that alone might garner large pharma interest even before the finish line IMO